AXIM Biotechnologies, Inc. is a San Diego-based research and development company that specializes in innovative diagnostic solutions for ophthalmological conditions. With a focus on improving the diagnosis of Dry Eye Disease (DED), AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions. Additionally, the company is actively involved in the development of rapid serological diagnostic tests for COVID-19 and early detection of cancer through the detection of SARS-CoV-2 neutralizing antibodies and active biomarkers.
Founded in 2014, AXIM Biotechnologies is a vertically integrated company that owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. With a strong commitment to research and development, AXIM has a proven track record of developing diagnostic solutions for various conditions based on the specific needs of their clients. Through strategic partnerships and a growing IP portfolio, AXIM Biotechnologies is dedicated to improving lives through their innovative diagnostic solutions.
Generated from the website